L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial.
Background: Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia.Findings: We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, mul...
| Publicado en: | Nutrition Journal Vol. 11; pp. 52 - 53 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | research randomized controlled trial Journal Article |
| Publicado: |
BioMed Central
2012
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104367980&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104367980 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 14752891 1CYY jtl: Nutrition Journal issn: 14752891 maglogo: N pubinfo: dt: 2012 vid: 11 pid: 24147 pub: BioMed Central artinfo: ui: 104367980 NLM22824168 2011684762 10.1186/1475-2891-11-52 NLM22824168 PMC3439338 104367980 ppf: 52 ppct: 1 formats: fmt: @attributes: type: P tig: atl: L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN)--a randomized multicentre trial. aug: au: Kraft, Matthias Kraft, Kathleen Gärtner, Simone Mayerle, Julia Simon, Peter Weber, Eckhard Schütte, Kerstin Stieler, Jens Koula-Jenik, Heide Holzhauer, Peter Gröber, Uwe Engel, Georg Müller, Cornelia Feng, You-Shan Aghdassi, Ali Nitsche, Claudia Malfertheiner, Peter Patrzyk, Maciej Kohlmann, Thomas Lerch, Markus M sug: subj: Cachexia Drug Therapy Carnitine Therapeutic Use Dietary Supplements Pancreatic Neoplasms Complications Vitamin B Complex Administration and Dosage Aged Body Composition Body Mass Index Cachexia Etiology Cachexia Physiopathology Double-Blind Studies Female Human Male Middle Age Nutritional Status Prospective Studies Randomized Controlled Trials Weight Loss Aged: 65+ years Middle Aged: 45-64 years Female Male ab: Background: Cachexia, a >10% loss of body-weight, is one factor determining the poor prognosis of pancreatic cancer. Deficiency of L-Carnitine has been proposed to cause cancer cachexia.Findings: We screened 152 and enrolled 72 patients suffering from advanced pancreatic cancer in a prospective, multi-centre, placebo-controlled, randomized and double-blinded trial to receive oral L-Carnitine (4 g) or placebo for 12 weeks. At entry patients reported a mean weight loss of 12 ± 2.5 (SEM) kg. During treatment body-mass-index increased by 3.4 ± 1.4% under L-Carnitine and decreased (-1.5 ± 1.4%) in controls (p < 0.05). Moreover, nutritional status (body cell mass, body fat) and quality-of-life parameters improved under L-Carnitine. There was a trend towards an increased overall survival in the L-Carnitine group (median 519 ± 50 d versus 399 ± 43 d, not significant) and towards a reduced hospital-stay (36 ± 4d versus 41 ± 9d,n.s.).Conclusion: While these data are preliminary and need confirmation they indicate that patients with pancreatic cancer may have a clinically relevant benefit from the inexpensive and well tolerated oral supplementation of L-Carnitine. pubtype: Academic Journal doctype: research randomized controlled trial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|